Comprehensive genomic and transcriptomic profiling revealed activation of receptor tyrosine kinase (RTK)‐mediated oncogenic (RAS/ERK and PI3K/AKT) signalling pathways, coupled with inactivation of tumour suppressors such as the lipid phosphatase PTEN and the RAS/ERK pathway inhibitor Sprouty2 (SPRY2), in advanced prostate cancer (Taylor et al, 2010). The gene discussed is SPRY2; the disease is prostate cancer.